Favorable effect of sodium–glucose cotransporter 2 inhibitor, dapagliflozin, on non‐alcoholic fatty liver disease compared with pioglitazone

Cho, Kyu Yong; Nakamura, Akinobu; Omori, Kazuno; Takase, Takahiro; Miya, Aika; Yamamoto, Kohei; Nomoto, Hiroshi; Kameda, Hiraku; Taneda, Shinji; Kurihara, Yoshio; Aoki, Shin; Atsumi, Tatsuya; Miyoshi, Hideaki

Favorable effect of sodium–glucose cotransporter 2 inhibitor, dapagliflozin, on non‐alcoholic fatty liver disease compared with pioglitazone

Cho, Kyu Yong; Nakamura, Akinobu; Omori, Kazuno et al.

Journal of Diabetes Investigation, 2021, 12(7), 1272-1277

Permalink : https://hdl.handle.net/2115/82892

このアイテムのアクセス数:752件（2026-08-13 13:14 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
JDI 12 1272-1277	pdf	661 KB	589

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/82892
タイトル	Favorable effect of sodium–glucose cotransporter 2 inhibitor, dapagliflozin, on non‐alcoholic fatty liver disease compared with pioglitazone
著者	Cho, Kyu Yong ; Nakamura, Akinobu ; Omori, Kazuno ; Takase, Takahiro ; Miya, Aika ; Yamamoto, Kohei ; Nomoto, Hiroshi ; Kameda, Hiraku ; Taneda, Shinji ; Kurihara, Yoshio ; Aoki, Shin ; Atsumi, Tatsuya ; Miyoshi, Hideaki
著者名 Cho, Kyu Yong
e-Rad_Researcher 70552420 著者名 Nakamura, Akinobu
著者名 Omori, Kazuno
著者名 Takase, Takahiro
著者名 Miya, Aika
著者名 Yamamoto, Kohei
e-Rad_Researcher 50862330 著者名 Nomoto, Hiroshi
e-Rad_Researcher 20826127 著者名 Kameda, Hiraku
著者名 Taneda, Shinji
著者名 Kurihara, Yoshio
著者名 Aoki, Shin
e-Rad_Researcher 20301905 著者名 Atsumi, Tatsuya
e-Rad_Researcher 30360902 著者名 Miyoshi, Hideaki
言語	英語
キーワード	Fatty liver
	Sodium–glucosecotransporter 2 inhibitors
	Type 2diabete
発行日	2021-07-08
出版者	John Wiley & Sons
収録物名	Journal of Diabetes Investigation
巻(号)	12(7)
ページ	1272-1277
抄録	Aims/Introduction Sodium?glucose cotransporter 2 inhibitors, as well as thiazolidines, suppress nonalcoholic fatty liver disease (NAFLD); however, few comparative studies have been reported. Dapagliflozin has shown non‐inferiority compared with pioglitazone for glycemic control, and superiority regarding weight reduction in patients with type 2 diabetes. We carried out a secondary analysis for the favorable effects of sodium?glucose cotransporter inhibitors for NAFLD. Materials and Methods In this multicenter, open‐label, prospective, randomized, parallel‐group comparison trial, patients taking pioglitazone for ≥12 weeks were randomly switched to dapagliflozin or continued pioglitazone for a further 24 weeks. The fatty liver index (FLI), consisting of body mass index, triglycerides, waist circumference and γ‐glutamyl transpeptidase, was used for the evaluation of NAFLD. Results A total of 53 participants with NAFLD (27 dapagliflozin; 26 pioglitazone) were included in this analysis. FLI decreased significantly in the dapagliflozin group (48.7 ± 23.4 to 42.1 ± 23.9) compared with the pioglitazone group (49.0 ± 26.1 to 51.1 ± 25.8; P < 0.01). Multiple linear regression analysis showed that the changes in FLI had a significantly positive correlation with changes in glycated hemoglobin (P = 0.03) and insulin level (P < 0.01) in the dapagliflozin group. Conclusion Dapagliflozin might be more beneficial than pioglitazone in patients with NAFLD. Improvements in FLI would be closely related to glycemic control.
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
権利情報	Creative Commons Attribution-NonCommercial 4.0 International
PISSN	2040-1116
EISSN	2040-1124
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.1111/jdi.13457